(Thanks to Atid-EDI) The US FDA has granted orphan designation for Teva’s TREANDA treatment for indolent B-cell non-Hodgkin lymphoma (iNHL). TREANDA is already used for patients with chronic lymphocytic leukemia (CLL).
http://www.tevapharm.com/Media/News/Pages/2013/1880493.aspx?year=2013
Lymphoma treatment gets exclusive status
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.